Human medicines European public assessment report (EPAR): Usrenty, ustekinumab, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Usrenty, ustekinumab, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/201

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised

Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026

Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness